Blueprint Medicines Receives FDA Orphan Drug Designation for Novel Drug Candidate for Treatment of Hepatocellular Carcinoma
"We believe BLU-554 represents a promising new approach for molecularly targeted therapy in HCC," said
Aberrantly activated signaling of FGFR4 may be a key driver in up to 30 percent of HCC patients, according to an analysis by
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the potential for BLU-554 to provide clinical benefit to patients, the potential benefits of orphan drug designation for BLU-554 and the estimated number of HCC patients whose cancer tumors have aberrantly activated signaling of FGFR4. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the delay of any planned clinical trials and/or development of
Logo - http://photos.prnewswire.com/prnh/20150605/221118LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-receives-fda-orphan-drug-designation-for-novel-drug-candidate-for-treatment-of-hepatocellular-carcinoma-300151325.html
SOURCE
Investor Relations: Hannah Deresiewicz, Stern Investor Relations, Inc., 212-362-1200, hannahd@sternir.com, or Media Relations: Naomi Aoki, Ten Bridge Communications, Inc., 617-283-4298, naomi@tenbridgecommunications.com